VANCOUVER, British Columbia, Feb. 22, 2011 /PRNewswire/ -- Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the IN3 West Investment in Innovation Conference on Thursday, February 24 at 11:05 AM PST. The conference is being held at the Venetian Hotel in Las Vegas.
Dr. Rewcastle will provide an overview of Enox's technology and its ability to embed nitric oxide into polymer medical devices rendering them antimicrobial. He will also review recently published independent data that shows that ionic silver coatings for medical devices are not as effective as hoped.
"There is a very significant clinical need for an effective non-antibiotic treatment to render medical devices antimicrobial," said Rewcastle. "Each year in the United States alone, hospital acquired infections kill hundreds of thousands of patients and cost the health care system tens of billions of dollars. Silver coatings were hoped to be an answer to increasing antibiotic but, based on recent publications, this does not appear to be the case. Our nitric oxide technology is uniquely positioned to answer this critical need of all healthcare systems worldwide."
"The IN3 West Conference is an ideal venue for Enox to present at," continued Rewcastle. "The participants consist of both venture capitalists and larger companies seeking to partner with emerging technologies. I am looking forward to the meeting and expect a very positive response."About Enox Biopharma Inc.Enox Biopharma, Inc. is an emerging biotechnology company with proprietary technology that embeds nitric oxide (NO) into polymer medical devices. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes, tympanostomy tubes and cosmetic implants. With the current CMS non-coverage of certain nosocomial infections